A Randomized, Double Blind Study of Cabozantinib vs Placebo in Patients with Advanced Neuroendocrine or Carcinoid Tumors after Progression on Everolimus (A021602)
A Randomized, Double Blind Study of Cabozantinib vs Placebo in Patients with Advanced Neuroendocrine or Carcinoid Tumors after Progression on Everolimus (A021602)
Trial Category:
Other Solid Tumor
Phase
III
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
For patients who have neuroendocrine or carcinoid tumors, and have progressed on the drug Everolimus, this study is looking at a new drug and comparing it to a placebo(no active drug) in order to assess whether the drug Cabozantinib adds anti-tumor activity.
